Generally speaking, Roche’s (ROG: SIX) immuno-oncology asset Tecentriq (atezolizumab) has struggled to keep up with the front-runners in the space in terms of trial results and approvals.
Bristol-Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) and Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) are seen as the dominant drugs among the first wave of I-O treatments, so the Swiss pharma giant was given something to shout about on Monday.
"These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of ES-SCLC"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze